OPTINOSE INC. - COMMON STOCK

Optinose Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights

07 Mar 2023 06:00:56 By Nasdaq GlobeNewswire

Optinose Announces Reporting Date for Fourth Quarter 2022 Financial Results

28 Feb 2023 15:30:00 By Nasdaq GlobeNewswire

Optinose Submits Supplemental New Drug Application for XHANCE Label Expansion

21 Feb 2023 06:00:01 By Nasdaq GlobeNewswire

Optinose Announces CEO Transition and Business Update

31 Jan 2023 06:00:01 By Nasdaq GlobeNewswire

Optinose Appoints Paul Spence as Chief Commercial Officer

15 Dec 2022 15:30:00 By Nasdaq GlobeNewswire

Optinose Announces Departure of Acting Chief Financial Officer

09 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

Optinose Announces Corporate Updates and Presentation at the 34th Annual Piper Sandler Healthcare Conference

30 Nov 2022 06:00:00 By Nasdaq GlobeNewswire

Optinose Announces Pricing of Public Offering of Common Stock and Warrants

21 Nov 2022 07:30:00 By Nasdaq GlobeNewswire

Optinose Announces Proposed Public Offering of Common Stock and Warrants

21 Nov 2022 05:12:44 By Nasdaq GlobeNewswire

Optinose Reports Third Quarter 2022 Financial Results and Operational Updates

10 Nov 2022 06:00:04 By Nasdaq GlobeNewswire

Optinose Announces ReOpen2 Presentation at the American College of Asthma, Allergy, and Immunology (ACAAI) 2022 Annual Scientific Meeting

09 Nov 2022 14:00:00 By Nasdaq GlobeNewswire

Optinose Announces Reporting Date for Third Quarter 2022 Financial Results

07 Nov 2022 14:00:00 By Nasdaq GlobeNewswire

Optinose Announces Late Breaking Abstract Podium Presentation at IDWeek 2022

21 Oct 2022 06:00:00 By Nasdaq GlobeNewswire

Optinose Announces ReOpen1 Abstract Selected for Presentation at the American Rhinologic Society Annual Meeting

06 Sep 2022 11:00:00 By Nasdaq GlobeNewswire

Optinose Reports Second Quarter 2022 Financial Results and Operational Updates

11 Aug 2022 06:00:03 By Nasdaq GlobeNewswire

Optinose Announces Reporting Date for Second Quarter 2022 Financial Results

08 Aug 2022 15:20:00 By Nasdaq GlobeNewswire

Optinose Announces that XHANCE Significantly Reduced Incidence of Exacerbations for Patients with Chronic Sinusitis in Landmark ReOpen Program

13 Jul 2022 06:00:00 By Nasdaq GlobeNewswire

Optinose Announces Additional Positive Results from ReOpen2 and Initial Results from Pooled Analyses of Both Trials in the ReOpen Program

08 Jul 2022 06:00:00 By Nasdaq GlobeNewswire

Optinose Announces Positive Top-line Results of ReOpen2, its second Phase 3 Clinical Trial of XHANCE for Treatment of Chronic Sinusitis

13 Jun 2022 06:00:01 By Nasdaq GlobeNewswire

Optinose Announces Departure of Chief Financial Officer

03 Jun 2022 06:00:37 By Nasdaq GlobeNewswire